MELBOURNE, Australia<\/span> and SAN FRANCISCO<\/span>, Nov. 22, 2021<\/span> \/PRNewswire\/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler<\/span>, M.D., Chief Executive Officer will participate in two upcoming virtual investor events:<\/p>\n

\n<\/p><\/div>\n

MST Financial Lifesciences & Biotech Fourm<\/span>
<\/b>Wednesday, November 24<\/span>^{th<\/sup> at 5:20 p.m. PST<\/span> (U.S.) \/ Thursday, November 25<\/span>^{th<\/sup> at 12.20 pm<\/span> AEST
A link to the live and recorded webcast will be available on the Alterity website.<\/p>\n}}

Benchmark Company Discovery One-on-One Investor Conference
<\/b>Thursday, December 2<\/span>^{nd<\/sup> (U.S.) \/ Friday, December 3<\/span>^{rd<\/sup> (Australia<\/span>)<\/p>\n}}

About Alterity Therapeutics Limited <\/b><\/p>\n

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia<\/span>, and San Francisco, California<\/span>, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.<\/a><\/p>\n

Authorisation & Additional information
<\/b>This announcement was authorized by David Stamler<\/span>, CEO of Alterity Therapeutics Limited.<\/p>\n

Contact: Investor Relations<\/b><\/p>\n

\n\n\n\n\n\n\n
\n
Australia<\/span><\/p>\n<\/td>\n
\n
US<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
Rebecca Wilson<\/span><\/p>\n<\/td>\n
\n
Remy Bernarda<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
E: WE-AUAlterity@we-worldwide.com<\/a><\/span><\/p>\n<\/td>\n
\n
remy.bernarda@iradvisory.com<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n
\n
Tp: +61 417 382 391<\/span><\/p>\n<\/td>\n
\n
Tp: +1 (415) 203-6386<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n
<\/p>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"
MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 \/PRNewswire\/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"),…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/98109"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=98109"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/98109\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=98109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=98109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=98109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}